Skip to content
Human-limitedGLP-1 agonist for non-alcoholic fatty liver disease

Semaglutide (Liver Health)

GLP-1 agonist for fatty liver & metabolic health.

Overview

Activates GLP-1 receptors on hepatocytes, reducing lipogenesis and increasing fatty acid oxidation.

Proposed mechanism

Semaglutide reduces liver fat by suppressing appetite, improving insulin sensitivity, and directly reducing de novo lipogenesis in hepatocytes.

What the evidence supports

Human data exists but the trials are small, short-term, or not yet replicated.

Graded Human-limited

Human data that exists but is thin: open-label work, single-arm studies, small cohorts, or observational follow-up without randomisation.

Key citations

Representative primary sources, including results that did not favour the compound.

  1. [1]

    Semaglutide in NASH

    · DOI:10.1056/NEJMoa2031482 · 2021

  2. [2]

    Semaglutide in NASH (2021)

    · · 0

Citation records in this build are illustrative placeholders for the design.

Reference information for research purposes. Not medical advice, and not a recommendation to use any compound. Many entries describe substances that are not approved for human use.